This is a news story, published by CNBC, that relates primarily to Zepbound news.
For more Zepbound news, you can click here:
more Zepbound newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
weight loss drug Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest tirzepatide shortage news, powdered tirzepatide news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
compounded tirzepatideCNBC
•Health
Health
86% Informative
The FDA announced Thursday that branded tirzepatide, the active ingredient in Eli Lilly's weight loss drug Zepbound , is no longer in short supply.
That decision will largely prevent compounding pharmacies from making and selling cheaper versions of the drug in the next two to three months .
It will also leave some patients in limbo, closing a niche, lucrative market for a cheaper alternative.
Pharmacy outsourcing facilities get an extra month , with a deadline of March 19 .
Compounding pharmacies may be allowed to continue making compounded tirzepatide in certain situations, trade group says.
FDA and OFA say they will provide an update in court by Jan. 2 to address "next steps in this litigation".
Compounding pharmacies such as Strive Pharmacy are operating as usual pending more updates to the legal fight.
Strive will largely stop making compounded tirzepatide by the February deadline if nothing further happens.
Compounding individual prescriptions for specific patients will make it harder for Strive to ensure that all of its safety procedures are still in place.
VR Score
85
Informative language
83
Neutral language
74
Article tone
informal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
15
Source diversity
10
Affiliate links
no affiliate links